Aflibercept, Bevacizumab, or Ranibizumab for Diabetic Macular Edema
New England Journal of Medicine, 2015 · paper · Clinical trials
A randomized trial of 660 adults comparing aflibercept, bevacizumab and ranibizumab injections for diabetic macular edema. Vision improved most with aflibercept at one year, but the authors report the difference came from eyes with worse starting vision and was not clinically meaningful in others.
0 findings
None that passed a second check.
2 minor (typos and the like; most checked by the judge only)
Typo "visual acuity" is printed run together as "visualacuity": "both initial-visualacuity subgroups" (p8) and "initial visualacuity loss was mild" (p9).
- p. 8 Discussion, first line of page
both initial-visualacuity subgroups
- p. 9 Conclusion paragraph
initial visualacuity loss was mild
Judge's note: Crops C003-a (p8, line 2) and C003-b (p9, line 3) both show "visualacuity" in the middle of a line, so this is not a text-layer artefact from a lost hyphen. Elsewhere the paper writes "visual-acuity". This is a cosmetic typo.
Second check: none (judge only)
Report a problem with this finding
Typo There is a stray space after the en dash in "resolution of central-subfield– involved diabetic macular edema" (p8).
- p. 8 Discussion, second paragraph
central-subfield– involved diabetic macular edema
Judge's note: Crop C004-a (p8, Discussion paragraph 2) shows a visible space between the en dash and "involved" in the middle of a line. This is cosmetic; it should read "central-subfield–involved".
Second check: none (judge only)